- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01105702
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
July 6, 2016 updated by: NYU Langone Health
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Treatment of high grade glioma (HGG) with anti-angiogenic therapy results in clinical improvement and prolonged progression-free survival (PFS).
However, mant patients experience diffuse recurrence and treatment failure.
This is a phase II trial testing the feasibility of adding lithium carbonate, previously shown to have anti-invasive properties in HGG, to bevacizumab and chemoradiation following surgical resection of HGG.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Summit, New Jersey, United States, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, United States, 10016
- New York University Clinical Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly diagnosed high grade glioma (WHO Grade III and IV)
- Brain magnetic resonance imaging (MRI) scan with gadolinium contrast
Patient must have normal organ and marrow function as defined below:
- Absolute neutrophil count >= 1,500/mm^3;
- Platelet count >=100,000/mm^3;
- Hemoglobin >= 10g/dL;
- Blood urea nitrogen and serum creatinine both =< 1.5 times upper limit of normal (ULN);
- Total bilirubin both =< 1.5 times ULN;
- SGOT and SGPT both =< 3 times ULN;
- Alkaline phosphatase =< 2 times ULN.
- >=18 years of age;
- Karnofsky Performance Score >= 70;
- Life expectancy >= 8 weeks;
- Negative serum or urine beta-hCG pregnancy test at screening for patients of child bearing potential;
- Men and women with reproductive potential must agree to use an acceptable method of birth control (surgical, hormonal or double barrier, ie, condom and diaphragm) during treatment and for 6 months after completion of treatment;
- Patient or their legal proxy must provide written informed consent prior to registration on study;
- Residual measurable disease.
Exclusion Criteria:
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study;
- Prior radiation therapy to the brain;
- Prior treatment with Chemotherapy or Targeted agent
- Previous (within last 5 years) or current malignancies at other sites except for adequately treated basal cell or squamous cell skin cancer in situ carcinoma of the cervix;
- (Uncontrolled High blood pressure >150/100
- Common Terminology Criteria Adverse Event 3.0 >= Grade 2 congestive heart failure (CHF);
- History of myocardial infarction within 6 months;
- History of stroke within 6 months;
- Clinically significant peripheral vascular disease;
- Evidence of bleeding diathesis or coagulopathy;
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of bevacizumab or anticipation of need for major surgical procedure during the course of the study;
- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to study enrollment;
- Urine protein/Creatinine ratio >= 2.0 at screening;
- Serious, non-healing wound, ulcer, or bone fracture;
- Inability to comply with study and/or follow-up procedures;
- Glioma showing active intratumoral bleeding;
- Patients on enzyme-inducing anti-epileptic drugs;
- Known Positive HIV-1, hepatitis B surface antigen, or hepatitis C antibody;
- Medications like nonsteroidal antiinflammatory drugs, antipsychotics, iodides, and angiotensin-converting enzyme inhibitor, If they are receiving them, they must have been discontinued for 7 days prior to initiating lithium;
- Any previous cytotoxic drug therapies, excluding corticosteroids and temozolomide concurrent with radiation therapy;
- Any known genetic cancer-susceptibility syndromes;
- Acute infection: any active viral, bacterial, or fungal infection that requires specific therapy.
- Active uncontrolled infection - examples include sexually transmitted disease, herpes, scrofula, malaria, etc.;
- Fever > 101.5 degrees Fahrenheit;
- Unstable or severe intercurrent medical conditions such as unstable angina, uncontrolled arrythmias, Crohn's disease, ulcerative colitis, psoriasis, etc.;
- Implantation of Gliadel wafers at surgery;
- Patients with organ allografts; and
- Allergies to reagents used in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TBL/RT
Cycle 1(One 42-day cycle)
Treatment Cycles 2-7 (28 days per cycle)
|
Other Names:
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-Free Survival (PFS)
Time Frame: Up to 50 months
|
PFS defined as time from date of diagnosis to most recent follow up, disease progression, or death.
Disease progress defined as either clinical deterioration or radiographic progressive disease on magnetic resonance imaging (MRI) per updated response assessment in neuro-oncology criteria (Wen, et al).
|
Up to 50 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Overall Survival (OS)
Time Frame: Up to 50 months
|
OS defined as time from diagnosis to most recent follow up or death.
|
Up to 50 months
|
Number of Patients With Grade 3 or 4 Adverse Events
Time Frame: The whole time while on treatment and 30 days after the treatment
|
Adverse events evaluated per CTCAE 3
|
The whole time while on treatment and 30 days after the treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Deborah Gruber, MD, New York University Cancer Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (ACTUAL)
April 1, 2014
Study Completion (ACTUAL)
April 1, 2015
Study Registration Dates
First Submitted
April 12, 2010
First Submitted That Met QC Criteria
April 15, 2010
First Posted (ESTIMATE)
April 16, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
August 4, 2016
Last Update Submitted That Met QC Criteria
July 6, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioma
- Brain Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Antimanic Agents
- Temozolomide
- Bevacizumab
- Lithium Carbonate
Other Study ID Numbers
- NYU 07-712
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownCancer | Metastatic Cancer | Metastatic Brain CancerChina
-
University of FloridaCompletedBrain Neoplasms | Brain Cancer | Brain Tumors | Seizure | Cancer of the Brain | Cancer of BrainUnited States
-
Eisai Inc.CompletedMetastatic Brain CancerUnited States
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Brain CancerCanada
-
InSightecActive, not recruitingGlioma | Metastatic Brain CancerCanada
-
Virginia Commonwealth UniversityUnited States Department of DefenseActive, not recruitingBrain Metastases, Adult | Cancer Metastatic to BrainUnited States
-
Stanford UniversityTerminatedCancer | Brain CancerUnited States
Clinical Trials on Temozolomide
-
Guangzhou Medical UniversityUnknownSmall Cell Lung Cancer | Metastatic CarcinomaChina
-
Bradmer Pharmaceuticals Inc.Terminated
-
University of SouthamptonBristol-Myers SquibbRecruitingCancer of Esophagus | Adenocarcinoma - GEJUnited Kingdom
-
Novartis PharmaceuticalsCompletedGlioblastomaAustralia, Spain, Canada, United States
-
Activartis BiotechCompleted
-
Peking Union Medical College HospitalBeijing Tiantan Hospital; Tianjin Medical University General HospitalUnknownMalignant GliomasChina
-
Yunpeng LiuUnknownExtensive Stage Small Cell Lung CancerChina
-
Yong-Kil HongNational Cancer Center, Korea; Samsung Medical Center; Seoul St. Mary's Hospital and other collaboratorsCompletedGlioblastomaKorea, Republic of
-
Medical University of South CarolinaTerminatedGlioma | Astrocytoma | Brain Tumor | Glioblastoma MultiformeUnited States
-
Merck Sharp & Dohme LLCTerminatedBreast Neoplasm | Brain Neoplasm | Second Neoplasm